ArticleRoyal Society open science2018
Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining.
Article in Royal Society open science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs.PLoS pathogens · 2026Article
- Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs.bioRxiv : the preprint server for biology · 2026Article
- Pulsatilla chinensis functions as a novel antihyperlipidemic agent by upregulating LDLR in an ERK-dependent manner.Chinese medicine · 2024Article
- Recent Advances in and Application of Fluorescent Microspheres for Multiple Nucleic Acid Detection.Biosensors · 2024Review
- Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance.Molecular oncology · 2024Article
- Smoking induces WEE1 expression to promote docetaxel resistance in esophageal adenocarcinoma.Molecular therapy oncolytics · 2023Article
- Regulating the cell shift of endothelial cell-like myofibroblasts in pulmonary fibrosis.The European respiratory journal · 2023Article
- A Descriptive Whole-Genome Transcriptomics Study in a Stem Cell-Based Tool Predicts Multiple Tissue-Specific Beneficial Potential and Molecular Targets of Carnosic Acid.International journal of molecular sciences · 2023Article
- Factor-specific generative pattern from large-scale drug-induced gene expression profile.Scientific reports · 2023Article
- Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.Cancer medicine · 2023Article
- Connecting omics signatures and revealing biological mechanisms with iLINCS.Nature communications · 2022Article
- Drug target inference by mining transcriptional data using a novel graph convolutional network framework.Protein & cell · 2022Article
- Comprehensive Survey of Recent Drug Discovery Using Deep Learning.International journal of molecular sciences · 2021Review
- Article
- CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer.Aging · 2021Article
- Cross-modal representation alignment of molecular structure and perturbation-induced transcriptional profiles.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2021Article
- signatureSearch: environment for gene expression signature searching and functional interpretation.Nucleic acids research · 2020Article
- Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning.Cancers · 2020Review
- An up-to-date overview of computational polypharmacology in modern drug discovery.Expert opinion on drug discovery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repurposing aims to find novel indications of clinically used or experimental drugs. Because drug data already exist, drug repurposing may save time and cost, and bypass safety concerns. Polypharmacology, one drug with multiple targets, serves as a basis for drug repurposing. Large-scale databases have been accumulated in recent years, and utilization and integration of these databases would be highly helpful for polypharmacology and drug repurposing. The Connectivity Map (CMap) is a database collecting gene-expression profiles of drug-treated human cancer cells, which has been widely used for investigation of polypharmacology and drug repurposing. In this study, we integrated the next-generation L1000-based CMap and an analytic Web tool, the L1000FWD, for systematic analyses of polypharmacology and drug repurposing. Two different types of anti-cancer drugs were used as proof-of-concept examples, including histone deacetylase (HDAC) inhibitors and topoisomerase inhibitors. We identified KM-00927 and BRD-K75081836 as novel HDAC inhibitors and mitomycin C as a topoisomerase IIB inhibitor. Our study provides a prime example of utilization and integration of the freely available public resources for systematic polypharmacology analysis and drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.